Expert Interview
With a Fresh Approval Finally in Hand, What's the Market Potential For YOSPRALA in Secondary Prevention Of Cardiovascular And Cerebrovascular Events In Patients At Risk For Aspirin-Associated Gastric Ulcers
Ticker(s): ARLZA doctor who is an expert in cardiovascular disease prevention and currently treats many patients with aspirin. This expert would have a detailed understanding of the YOSPRALA value proposition, label and data.
How many patients do you currently treat with Aspirin as a secondary prevention of Cardiovascular and Cerebrovascular Events?
Added By: joe_mccannDo you think that the value proposition of YOSPRALA makes sense? How many of your patients do you currently not recommend aspirin to due to gastric ulcer concerns?
Added By: joe_mccannIf your patients with risk of ulcers, do any take an enteric-coated aspirin with a PPI successfully now?
Added By: joe_mccannDo you think a payor will understand this value proposition? Would you think that a required failure (getting an ulcer or having a cardiac issue), on enteric-coated aspirin + a PPI, is a possible requirement before reimbursement or would that be too dangerous a requirement?
Added By: joe_mccannAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
